Value frameworks scoring of a new oncology treatment and comparators

What is market access?

For pharmaceutical and biotechnology manufacturers, enabling faster patient access to therapies is a key challenge. An effective market access strategy helps them solve the challenge.   Market access: a basic definition In the simplest terms, market access is about getting the right treatment to the right patient at the right time, and possibly even at …

Indication-based pricing: your free eBook download

Optimize the value of assets in development across multiple indications

Achieving a variable price by indication: free eBook download

Achieve a variable price by indication

PRMA Consulting Expert Advisory Group on Complex Pricing (EAGCP): Focus on gene therapies

A recent meeting of complex pricing experts focused on the challenges and solutions for pricing and reimbursement in the area of innovative cell and gene therapy products. The bespoke group shared knowledge from a range of countries and different roles within healthcare systems, to bring a practical and pragmatic approach to issues related to pricing. …

Digitally transforming health technology assessment (HTA) submission processes

Evaluate how digital technology can better enable processes and requirements

Over the last few years we have seen how digital technology has been harnessed to improve health outcomes. With the rapidly evolving market access landscape, we are now on the cusp of a huge acceleration in the use of digital applications to explore value options, gain strategic advantage and provide innovative market access solutions. To …

Using payer perspectives to inform evidence generation strategies for successful market access

Recommendations for an ophthalmology launch plan in the EU

Transforming the market access landscape: the role of digital applications

Pharmaceutical and biotechnology companies are turning to technology more frequently to solve business issues, and are increasingly using digital technology to optimize market access for their products.

Clarity or confusion: the role of value frameworks in oncology

This on-demand webinar uses case studies to illustrate key concepts in the emerging role of value frameworks in oncology.

Exploring the challenges for pricing and reimbursement of high-cost combination therapies

Gain market access insight from payer and pricing experts from across the EU into: the reimbursement mechanisms for combination products the access challenges these mechanisms present for new innovative combinations the scope for potential solutions the policy direction in France, Germany, and the UK

Strategic and tactical support achieves HTA success

Strategic projects to inform commercialization decisions in RSV

Biosimilars: market access considerations

As the biosimilar market expands, payers are looking to take advantage of potential budget savings.

Landscape assessments and market access strategy for CDx-drug pairings

Accelerating decision-making for international market access

Does 1+1 always equal 2? Valuing combinations

With more drugs coming to market, and the growing number of possible combinations, this on-demand webinar discusses how combinations of drugs are evaluated by payers.

Patient-centricity: a crucial approach for market access?

As the focus of healthcare providers shifts to placing patients at the center of their activities, it is important for the pharmaceutical industry to adopt more patient-centric ways of working.

Designing effective managed entry agreements: insight from Spain

A recent meeting of complex pricing experts from across the EU5 countries focused on the variability among countries of payers’ and policy-makers’ attitudes to MEAs, and the practical challenges for implementation capable of satisfying a range of country requirements. Here we summarize the insights from the Spanish discussion. Budget caps are still the most common …

Strategic roadmap for optimized global market access for CAR-T

Market access for PD-1 inhibitors: where are we now?

This on-demand webinar shares our thoughts on evaluations for PD-1 inhibitors and assess some of the implications for manufacturers.

Recommendations for successfully developing managed entry agreements

A recent meeting of complex pricing experts from across the EU5 countries (France, Germany, Italy, Spain, and the UK) focused on the variability among countries of payers’ and policy-makers’ attitudes to managed entry agreements (MEAs), and the practical challenges for implementation capable of satisfying a range of country requirements. Here we summarize the insights from …

Review of CAR-T assessments and implications for novel agents

Bolstering payer discussions to solve persistent challenges

Five strategies for CAR-T pricing and reimbursement success

CAR-T therapy: the future begins to take shape

Managed entry agreements: regional and national insight in market access

Managed entry agreements: theory and principles in market access

Achieving a positive HTA outcome with insight from payer and clinician advisory boards

Assessing evidence generation strategies for an asset with a novel biomarker in a rapidly evolving landscape

Exploring the challenges for pricing and reimbursement of high-cost combination therapies

Gain market access insight from payer and pricing experts from across the EU into:

Anticipate evidence needs early on and accelerate development of focused evidence generation activities

Patient-centricity: shaping value generation for HTA and market access

This webinar focuses on different European patient engagement models and guidelines. It also provides insight into how to shape value from an HTA and market access perspective.

Four recommendations to kick-start the digital transformation of your market access processes

Digital transformation in pharmaceutical and biotechnology market access, and four recommendations for those who are keen to drive change.

Protect your market access data: the value of ISO27001

In this market access update, we summarize the importance of reviewing your supplier’s information security standards.

Identifying critical risks for payer decision-making

Case studies

Protecting your market access data. 10 questions to ask your suppliers

Suppliers who provide you with software-as-a-service (SaaS) need to gather, analyze, and transfer market access data on your behalf. You may send data to them, or upload directly to their application. To avoid business risks, it is essential to understand how the supplier manages your data, and how they are protected, handled, stored, and retained …

Exploring the benefits of cloud computing for market access.

In a couple of sentences, what is cloud computing? Cloud computing provides pooled resources and services via the internet to users, on-demand, 24/7. At PRMA Consulting we capitalize on cloud services to transform the market access process of leading pharmaceutical and biotechnology companies. How is cloud different to the traditional data centers that market access …

Top-5 pharma discovers a new way to evaluate pricing opportunities

Critically evaluating pricing and access risks and opportunities for an asset under different clinical development scenarios

Measuring survival benefit in oncology health technology assessments

Immuno-oncologic therapies have frequently produced unorthodox survival profiles, particularly when compared with cytotoxic chemotherapy drugs. Delayed onset of treatment effect, “pseudo-progression”, subgroups of durable responders, bridging to curative therapy, and other pronounced forms of heterogeneity of efficacy are potential contributors to this. In these circumstances, the conventional toolkit for measuring survival benefit, established when cytotoxic …

Blocking competitor intrusion in competitive pharmaceutical markets

Market access considerations for CAR-Ts: insights from ASH

This on-demand webinar reviews key learnings from the 2017 ASH annual meeting.

Managed entry agreements: regional and national insight

Managed entry agreements: theory and principles

Demonstrating value using a new approach to economic modeling

CLIENT SITUATION Using the PRMA Healthcheck® late module, a top-20 pharmaceutical company quickly identified an opportunity to engage with HTA agencies and an expert technical panel in their exploration of potential approaches to cost-effectiveness modeling.

Improve health technology assessment submissions

Achieve up to 80% auto-population of your first draft submission

Pricing and reimbursement of CAR‐T in Germany

CAR-T therapy: the future begins to take shape

Incorporating the patient voice in market access

The patient voice is firmly established as key to determining value in healthcare. This means that pharmaceutical and biotechnology manufacturers should evaluate and evolve how they engage with patients.

Combinations: P&R considerations

Evidence synthesis and development of economic models

Improving pharmaceutical portfolio management and decision-making for early assets

Learn how this top-10 company refined its portfolio management strategy for pre-clinical assets. Capitalizing on the latest digital technology in the pharmaceutical industry, it successfully restructured market access frameworks and prioritized investment decisions.

Payer perspectives on cell and gene therapies: opportunities and challenges

In this on-demand webinar, Professor Stephen Palmer from the University of York discusses his work on the assessment of regenerative medicines and cell therapy, and the UK and EU payer perspective on the potential value of these therapies.

The relevance of patient perspectives to value

In the first of our two-part series, we explore the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access.

Creating compelling real-world evidence that supports favorable HTA

Indication-specific pricing: the obvious solution

This on-demand webinar examines the challenges and opportunities for manufacturers and payers in implementing an indication-specific pricing strategy.

Potential solutions for pricing and reimbursement of high-cost combination products

Pricing and reimbursement solutions for high-cost combination therapies

Pricing and reimbursement in Canada: a market access update

Here’s our round up of healthcare market access news from Canada over recent months.

Developing a market access and HEOR roadmap in a rapidly evolving landscape

Maximize the pricing and market access potential of your early pipeline

CAR-T therapy: the future begins to take shape

This on-demand webinar reviews the early experiences of the first CAR-T products to be licensed, enter into pricing and reimbursement (P&R) processes, and move towards delivery in a commercial setting.

Overcoming the market access challenges associated with high-cost combination therapies

The scale and potential impact of high-cost combinations coming to market in the next 2-3 years will force a significant change in pricing and reimbursement policies. Steve Fountain evaluates some of market access challenges for pharmaceutical manufacturers using insights gained from the PRMA Innovative Pricing Panel.

Free eBook: how to accelerate the generation of simultaneous, high-quality HTA submissions

How to accelerate the generation of simultaneous, high-quality health technology assessment (HTA) submissions. An introduction to the PRMA Navigator^®, a breakthrough HTA digital application.

Critically evaluating pricing and access risks and opportunities for an asset under different clinical development scenarios

Developing an international market access strategy to optimize pricing and reimbursement opportunities

Managed entry agreements: lessons from EU5

This on-demand webinar reviews the learnings on managed entry agreements in the EU5 and case studies of innovative approaches.

ISPOR Europe 2019

Digitalizing your market access processes will leave you wondering how you managed the “old way” for so long

How digital technology is transforming market access in the Asia-Pacific region

Where pharmaceutical market access is broader than formal payer assessments, for example in many Asia-Pacific markets, we have developed robust value assessment frameworks that integrate into the PRMA Healthcheck® digital application. This case study from a leading pharmaceutical manufacturer explains how the PRMA Healthcheck® has helped the organization to: assess market access and commercialization risks …

Do your global value dossiers contain these 5 common omissions?

Within the health technology assessment process, effective communication of global strategy and product value to affiliate teams is crucial.

Developing an economic model to optimize market access opportunities

Development of a value story, GVD, and payer materials

Orphan drug re-assessments in Germany: the impact on additional benefit and price

In Germany, the additional benefit (AB) of orphan drugs with annual sales below €50 mn is deemed proven by the marketing authorization. The G-BA determines only the extent of AB, from abbreviated submissions. However, when annual sales exceed €50 mn, a re-assessment is triggered, requiring a full submission followed by price re-negotiations with the GKV-Spitzenverband. …

Do market access withdrawals impact patient access to treatment in Germany?

In this new market access study, Monika Behrens, explores the impact of G-BA resolutions and subsequent market withdrawals on access to treatments for patients. In Germany, the G-BA determines the additional benefit (AB) of new therapies relative to the appropriate comparator therapy (ACT). For products without a (proven) AB, annual therapy costs cannot exceed those …

Watch and vote in the 2019 Health Economics Innovation Series

We are proud to announce that the PRMA Navigator® digital application has been shortlisted for the 2019 Health Economics Innovation Webinar Series: big ideas accelerating change in health economic and outcomes research (HEOR), real-world evidence (RWE), market access (MA), and health technology. The smarter digital market access solution for pharmaceutical and biotechnology clients The 2019 …

Mapping patient involvement in NICE appraisals of oncology products

Understanding the value of patient involvement is crucial to efforts to encourage patients and their representatives to participate in health technology assessment (HTA). This study sought to understand the extent of patient involvement in oncology single technology appraisals (STAs) by NICE, and the key issues that patients focus on. STA committee papers for oncology indications …

Future proofing for the 2020s market access trends

This on-demand webinar discusses the emerging trends in marketing access and anticipates how successful pharmaceutical and biotechnology manufacturers will prepare for competitively advantageous product launches in the early 2020s. 

Digital innovation empowers global teams and local affiliates to shorten the time to market access

Digitally transforming health technology assessment (HTA) submission processes

61st ASH Annual Meeting and Exposition

Digitalizing your market access processes will leave you wondering how you managed the “old way” for so long In recent years, healthcare has gone digital: from artificial-intelligence-driven diagnostics, through to wearable technology and health apps. The pharmaceutical industry has also embraced digital efficiencies relating to internal processes, from drug discovery to drug development and packaging.Arguably, …

Estimating the eligible patient population for a targeted oncology therapy

EUnetHTA joint clinical assessments: where have we come from and where are we going?

This on-demand webinar explains the evolution of EUnetHTA and its influence to date on EU market access, and outlines the scenarios for the future development of this initiative.

The Fierce Innovation Award identifying outstanding innovation in Life Sciences

The Fierce Innovation Report featuring the PRMA Navigator® digital application: driving high-quality, simultaneous HTA submissions Led by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Report for Life Sciences identifies outstanding innovation that is driving improvements and transforming our industry.The latest innovative technologies that make the greatest impact for biotech and pharma companies are …

Finalist in the HealthEconomics.com’s 1st Annual HEOR and RWE Innovation Webinar Series: the PRMA Navigator^®

Digital transformation of HTA submission strategy with the PRMA Navigator^®, finalist in the HealthEconomics.com HEOR and RWE Innovation Webinar Series

Payer insight: 5 ways to get the most from your advisor interactions

Everyone in pharmaceutical market access is looking to get the most out of advisor interactions. This can’t be entered into lightly; the right blend of minds will lead to meaningful payer insight, actionable feedback, and advice. If you are working in pharmaceutical market access, you’ll be familiar with these challenges: How do you get early …

This top-5 pharma company chose the PRMA Navigator® to accelerate the generation of simultaneous HTA submissions and achieve up to 80% auto-population of their first drafts

Managed entry agreements: theory and principals

Managed entry agreements: theory and principles

Managed entry agreements: learnings for successful development from a UK perspective

A recent meeting of complex pricing experts from across the EU5 countries (France, Germany, Italy, Spain, and the UK) focused on the variability among countries of payers’ and policy-makers’ attitudes to managed entry agreements (MEAs), and the practical challenges for implementation capable of satisfying a range of country requirements. Here we summarize the insights from …

How to identify the potential for commercial success in early-stage product development

In early-phase value-driven development, it’s never too early to start thinking about commercial success. The PRMA Healthcheck® digital application will help you develop your strategic rationales at this critical .   The PRMA Healthcheck® assessments of early-phase assets help you to identify the potential for commercial success and shape direction and strategy at the earliest …

The influence of the patient voice in regulatory and health technology assessment activities

In the second of our two-part series, we explore a patient-centric approach to market access.

Accelerate the time to patient access with the PRMA Navigator^®

The PRMA Navigator^® digital application is accelerating the simultaneous generation of high-quality HTA submissions to allow patients faster access to new therapies. 

Transforming value and access outcomes in the Asia-Pacific region

Transforming value and access outcomes in the Asia-Pacific region

Are you in touch with the latest payer thinking?

Sanjeev Gogna, Senior Director at PRMA Consulting, looks at how technology is putting dynamic payer thinking at the fingertips of its users. You partner with leading pharmaceutical and biotechnology manufacturers on their market access projects. What challenges do you most commonly see? In some disease areas, payer and health technology assessment (HTA) expectations are changing …

The things you need to know about the digital transformation of primary research

In the rapidly evolving market access landscape, it’s important to quickly identify current payer perspectives to determine future trends. High-quality, rapid primary research can be key to fast-forwarding your strategy. Fleur Hogg, Head of the International Experts Group at PRMA Consulting, discusses 3 ways that new technology is helping market access professionals gain cost-effective, real-time …

Digitization in primary research: a smart addition to traditional market access research methods

From her experience working in primary research with payers and advisors, Fleur Hogg explains how digital transformation is helping clients gain rapid insights and competitive, market access advantage. What’s your role and background in primary research for market access? I’m the PRMA Consulting Head of the International Experts Group. We build relationships with key payers …

How to drive payer submission readiness for your late-phase products

The PRMA Healthcheck® digital assessments of late-phase pharmaceutical assets help you to bring a clear understanding of the risks and opportunities in multiple markets based on current payer requirements. This collection of case studies from leading pharmaceutical manufacturers explains how the PRMA Healthcheck® helps organizations to: focus attention on the key issues that will impact …

Healthcheck assessment for novel asset in moderate to severe rheumatoid arthritis

Proactively managing HTA challenges for follow-on indications in an orphan disease

How a leading pharma company gained significant market access insights prior to launch

This ebook explores how a leading pharmaceutical company gained an in-depth understanding of the latest payer thinking across rapidly evolving global markets.

Driving market access success in the US

Pharmaceutical market access requirements vary greatly by payer archetype in the US.

Market access roadmap in hemophilia B

PRMA Consulting expands its US presence

The go-to consulting partner for pricing, reimbursement, and market access strengthens its dedicated support of US pharmaceutical manufacturers through its new New York office.

Understanding the impact of the ESMO value framework and its revisions to existing and pipeline oncology assets

Emerging biomarker in a hemato-oncology indication

Up to 30% of global HTA template requirements may not be met by a traditional GVD

Payer insight: 5 ways to get the most from your advisor interactions

Everyone in pharmaceutical market access is looking to get the most out of advisor interactions. This can’t be entered into lightly; the right blend of minds will lead to meaningful payer insight, actionable feedback, and advice. In this market access update, Fleur Hogg shares some recommendations to help you get the most out of your …

Wellbeing at PRMA Consulting

There is an increasing awareness within corporate organizations of the importance of our emotional fitness. In this update, Christina Lawrence explains how PRMA Consulting is encouraging colleagues to consider the role that inner calm and inner strength can play in developing a happier, more engaged, motivated, resilient, and productive team. How did you evolve your …

COVID-19: how your market access can fly even when you are grounded

As the novel coronavirus (COVID-19) continues to spread around the world, is this an opportunity to re-think the way that market access specialists do business?

Home working: 6 tips for fostering team connectivity in times of distance and disruption

In this time of enforced ‘social distancing’ and ‘self-isolation’, it is easy to forget that there can be significant workplace benefits to stopping and slowing down.

Wherever we work, we work together

In these exceptional times we value everyone who dedicates themselves to our care and support, regardless of their own health. It is reassuring to know that healthcare professionals, manufacturers, and colleagues, wherever they are, are working together to enable faster patient access to therapies that improve health outcomes. We are proud that across our network …

Reducing market access risk: how digital technology is strengthening strategies

Developing innovative pharmaceutical products is a lengthy process with no guarantee of success at the end. Manufacturers struggle with coordinating strategy internally and incorporating multiple payer requirements in clinical development programs. In this market access update, Bharath Rao, Product Owner of Digital Applications at PRMA Consulting, explains how a digitally enabled assessment process reduces the …

Payer and HTA submissions: how digital technology is transforming market access processes

Claire Chadwick, HTA Manager at PRMA Consulting, explains how technology is helping market access professionals navigate the evolving challenges of HTA and payer submissions. What challenges do pharmaceutical and biotechnology market access professionals face when developing HTA and payer submissions? Successfully navigating HTA and payer submissions to achieve favorable pricing and access across multiple products …

WEConnect: Connecting Women’s Enterprises with Global Opportunities

  PRMA Consulting is proud to be a member of WEConnect: Connecting Women’s Enterprises with Global Opportunities global network. This recognizes our commitment to diversity and inclusion and our membership with organizations that share that commitment. WEConnect certifies women’s business enterprises based outside of the US that are at least 51% owned, as well as …

Breaking boundaries in market access: PRMA Consulting annual company meeting 2020

The theme for the PRMA Consulting annual company meeting 2020 was “Breaking Boundaries” and, aptly, it took place in Lisbon, Portugal, where explorers, such as Vasco De Gama and Ferdinand Magellan embarked on their voyages of discovery. The meeting truly captured the pioneering spirit that has helped our organization develop into an international consultancy that …

Navigating the updated 2020 ICER value assessment framework

In this webinar, US subject matter experts will provide an overview of changes in the recent update to the ICER value assessment framework (VAF), released in January 2020.

How collaboration and connectivity can accelerate payer submissions and drive faster patient access

Sotiria Papanicolaou explains how the combination of digital innovation and expert insight is removing roadblocks and speeding up the generation of payer submissions for pharma. The road to health technology assessment (HTA) and payer submissions is paved with complexity. Pharma’s mission is simple: to minimize the time between regulatory approval and market access, ensuring in …

Digital transformation: shaping the future of market access

In this update on digital transformation in market access, Bharath Rao, Product Owner of Digital Applications at PRMA Consulting, asks what could tomorrow look like?

ICER 2020 value assessment framework: 7 updates that market access professionals need to understand

In this market access report, Nicole Lodowski provides an overview of the ICER value assessment framework and explains the 7 key areas that have been updated in 2020. The Institute for Clinical and Economic Review (ICER) is an independent healthcare research organization in the US. ICER evaluates the clinical and economic value of prescription drugs, …

Why on-demand insight is key to successful payer submissions

In the digital age, on-demand innovation is changing the way we live – redefining everything from how we watch TV to how we pay our bills. It’s also setting new expectations in the workplace, transforming the way we access and share data, and helping organizations collaborate and make better-informed decisions. With ‘anytime, anywhere’ access to …

The evolution of the PRMA Healthcheck^® for US payer archetypes

The PRMA Healthcheck® digital application provides a systematic and robust assessment of the market access risks and opportunities for your assets, based on the treatment landscape and evolving payer needs. This session will introduce upcoming changes to the PRMA Healthcheck® application from a US perspective.

Preparing for ICER assessments: key recommendations for manufacturers

In this free market access whitepaper, Nicole Lodowski, Senior Director and PRMA US Practice Lead, explains how pharmaceutical and medical device manufacturers can prepare for the ICER assessment process.

Completing the puzzle: market access in Asia-Pacific

The Asia-Pacific (APAC) region may be the world’s second-largest pharmaceutical market – but it’s also one of the most complex when it comes to market access. In the major Asian markets – such as China, Japan, Singapore, and South Korea – policy isn’t just diverse, it changes rapidly. Moreover, with very little information in the …

Digital transformation in market access: don’t get lost in translation

Digital transformation is shaping the future of market access. Across all business sectors, technology is changing the way organisations interact with internal and external stakeholders, providing faster access to information and more efficient global collaboration. For pharma, the opportunity to transform market access through digital innovation is significant. However, getting there isn’t simply about optimising …

Why understanding payer archetypes is key to US market access

Until recently, pharma’s biggest market access challenge in the US has been learning to navigate “known unknowns”. Suddenly, however, long-standing unknowns – like the future of the Affordable Care Act, the nature of pricing reforms, or the influence of the Institute for Clinical and Economic Review (ICER) – are being set in a whole new …

PRMA Healthcheck^® for assets in early stages of clinical development

The PRMA Healthcheck® digital application provides a systematic and robust assessment of the market access risks and opportunities for your assets, based on the treatment landscape and evolving payer needs.

How will Covid-19 shape the evidence assessed by payers and HTA decision-makers?

As the Covid-19 pandemic continues to affect the health and economic climate, pharmaceutical manufacturers are focused on ensuring that they can deliver clinical trial results that support regulatory approval while minimizing or avoiding delays in the approval process. Although regulators have been issuing guidance on Covid-19, the consequences for health technology assessment (HTA) have not …

PRMA Healthcheck^® for assets in early stages of clinical development

The PRMA Healthcheck® digital application provides a systematic and robust assessment of the market access risks and opportunities for your assets, based on the treatment landscape and evolving payer needs.

PRMA Consulting announces its new office opening in Singapore

Jayne Sykes, Partner at PRMA Consulting, announces a new office opening in Singapore and explains how the company is shaping the future of market access for clients in the Asia-Pacific region. I am delighted to announce the opening of our first Asia-Pacific office in Singapore. It is an important step towards realizing improved market access …

Co-creation of a value assessment framework for early assets in the Asia-Pacific region​

Assessment framework of access landscape, reimbursement, and development plan for early pipeline assets

Framework to assess the early commercial and market access potential of an asset

Partnership with client’s Asia-Pacific team on regional activity and evidence roadmaps

CMS releases its annual IPPS final rule: key updates for manufacturers

On September 2, 2020, CMS released its annual Inpatient Prospective Payment System (IPPS) final rule, which applies to hospital discharges occurring on or after October 1, 2020 and will impact approximately 3,200 acute care hospitals across the US. While the ruling is made up of enormous detail across a 2,160-page document, there are several key …

PM Society Digital Awards: market access award winner

We are pleased to announce that the PRMA Healthcheck® digital application, a unique and innovative market access solution, has been chosen as the silver award winner in the market access category of the PM Society Digital Awards. The prestigious PM Society Digital Awards competition invites entries from organizations across the globe that deliver meaningful outcomes …

Cornerstones of ‘fair’ drug coverage: ICER and OHE release new white paper

On 28 September 2020, the Institute for Clinical and Economic Review (ICER), in collaboration with researchers at the Office of Health Economics (OHE) in the UK, published a new white paper: Cornerstones of ‘Fair’ Drug Coverage: Appropriate Cost-Sharing and Utilization Management Policies for Pharmaceuticals. The aim of the paper was to examine whether specific cost-sharing …

Driving market access readiness in the US through a unique digital application

What US market access teams should know about digital transformation.

Transforming your market access in Asia-Pacific

The Asia-Pacific region is critical to the future growth plans of pharmaceutical manufacturers and PRMA Consulting are leading ground-breaking market access projects in the region. These slides are from our on-demand webinar “Transform your market access in Asia-Pacific” where regional market access experts offer recommendations for: Assessing market access and commercialization risks, opportunities, and evidence needs …

Digital technology is transforming market access, but insight has a human heartbeat

It’s often said that foresight is the key to business success. That’s certainly true in the pharmaceutical industry, where anticipating evidence requirements early in a drug’s clinical development can be instrumental in securing optimal market access further down the line at launch. The foundations of successful market access strategies are typically laid in Phase 3 …

3 reasons to pursue a career in market access consultancy

There’s no doubt that a career in market access at PRMA Consulting offers great personal reward and a pathway for progression. Ask any professional in the pharmaceutical or biotechnology industries, and they will tell you that the sector is constantly looking to the future. If you’re keen to help manufacturers give patients faster access to …

The PRMA Healthcheck^®: the future of market access in Asia-Pacific

The PRMA Healthcheck® digital application provides a systematic, robust, and consistent approach to analyzing the many factors that influence pricing, reimbursement, and market access in the Asia-Pacific region.

Take your market access to the next level: your free digital transformation eBook

Taking the mystery out of digital transformation: an enlightening collection of articles, case studies, and on-demand webinars for market access professionals.

Managed entry agreement frameworks for rare disease products

Early scientific advice for a product in development for a rare cardiovascular disease

Market access and pricing opportunity for an asset in development for a rare and progressive form of liver disease

The PRMA Navigator^® digital application auto‑generates HTA submissions for an orphan drug

Well-being initiatives that work

In her latest update, Christina Lawrence, Head of People at PRMA Consulting, explains the importance of well-being at work and offers some proven quick wins for employers wishing to promote their well-being initiatives. The phrase ‘well-being at work’ is being used quite widely right now. Is ‘well being’ the fashionable buzzword in Human Resources? I …

A career development framework for market access consultancy

In this update we explain how the PRMA Consulting Career Development Framework helps colleagues to take responsibility for driving their career development.

Why culture is king in employers of choice

Organisational culture has never been more important. As the modern workplace is redefined by a global pandemic, experts predict that the businesses who emerge strongest will be those that had their culture nailed long before lockdown struck. They’re almost right, there’s just one crucial caveat: company culture is never ‘job done’ – it’s fluid, dynamic …

Why wellbeing at work is no longer a company perk

In this update, Christina Lawrence Head of People, explains why she is pleased that wellbeing at work is now recognised as a business strategy across many sectors and no longer deemed a “company perk”. As PRMA Consulting’s People Director and Mental Health First Aider, I am a champion of employee health and wellbeing, and normalizing …

The importance of core values for wellbeing at work

In this update, Christina Lawrence, Head of People and Mental Health First Aider, shares insights from a wellbeing at work session at PRMA Consulting. As part of a supportive program, initiated during the COVID-19 pandemic, this session offered colleagues the opportunity to explore the importance of core values in both work and personal environments. Your …

Employee satisfaction survey: the importance of colleague engagement at PRMA Consulting

Each year, PRMA Consulting employees are offered the opportunity to give feedback in an employee satisfaction survey. In this update, Christina Lawrence, Head of People, summarizes the latest survey results and explains why this form of employee engagement is so important. Why does PRMA Consulting conduct an employee survey each year? Our employees are our …

Payer risk assessment and evidence generation planning using the PRMA Healthcheck^®

Market access roadmap for an ultra-orphan drug for a genetic cardiovascular disorder

Take your market access to the next level: your free digital transformation eBook

Taking the mystery out of digital transformation: an enlightening collection of articles, case studies, and on-demand webinars for market access professionals.

Market access strategies and services for Asia-Pacific

The Asia-Pacific region is critical to the growth plans of many pharmaceutical and biotechnology manufacturers. As Ye Huang explains, PRMA Consulting is leading several exciting and ground-breaking market access projects in the region. Watch the complete webinar: Transform your market access in Asia-Pacific Keeping up with the changing market access landscapes in the Asia-Pacific region …

Five ways to break down the silos that stall digital transformation

One of most common obstacles to digital transformation is siloed working. In this digital market access update, Onisim Gabrian recommends five ways to overcome this challenge to achieving an effective digital culture. There are many reasons why a digital culture should matter to an organization. A digital culture enables the meeting of minds and disciplines. …

Value assessment and integrated evidence generation planning for mental health assets

Landscape assessment to inform trial design and payer value positioning using the PRMA Tracker^®

Helping you get the most market access value from your digital applications

In this update, Rozz Chowdhury (she/her), Client Excellence Manager, explains how she helps clients to accelerate their market access strategies, using the PRMA digital applications. The PRMA digital applications help you to unlock and optimize your product’s value from early development through to successful country submissions. We are using our digital applications to transform market …

Development of a GVD aligned with core content requirements of local payer submission templates

Implications of a companion diagnostic test for market access of a novel product in GBM

Mapping orphan drug policies and pathways across 12 markets​

10 ways to help manage stress when working from home

Read the complete article: “Beating work-related stress”

Development of payer materials for a schizophrenia treatment

A day in the life of a pharmaceutical market access consultant

Have you ever wondered what is it like to work in pharmaceutical market access consultancy? Or what types of jobs may be available in pricing and reimbursement? Two of our team give an insight into their typical working day. Jennifer Sander, Market Access Consultant I am based in PRMA Consulting’s US office where I work …

Evaluating the evidence requirements to support the market access of a novel monitoring device into the NHS

Tips for dealing with the stress of working from home

Working from home can be a challenge and could lead to stress levels that are difficult to manage alone. In this update, we provide tips to help home workers combat some common causes of work-related stress. A recent survey of US businesses1 reports that over 69% of workers are experiencing symptoms of stress and burnout …

Go-to market access consultancy welcomes Bharath Rao as Digital Product Owner

PRMA Consulting announces a new hire in the company’s digital team: Bharath Rao joins the organization as Digital Product Owner. “Creative connections and communications across people, technology, and approaches are what make the difference in today’s market access landscape,” says Bharath. “It was obvious to me that there couldn’t be a better consultancy and digital …

Recommendations for driving your journey to digital excellence

This free, 15-minute webinar provides key recommendations for manufacturers seeking to confidently fuel their strategies and drive stronger market access outcomes leveraging the experience and digital solutions of PRMA Consulting.

Beating work-related stress

Unmanageable workplace stress does not just affect the individual, it can damage the organization and impact its clients. Work-related stress has reached a point where it is damaging US businesses to the cost of more than US$300 billion a year.1 As part of her employee wellbeing series, Christina Lawrence, Head of People, considers: How can …

PRMA Consulting named one of Pharma Tech Outlook’s top consulting companies

PRMA Consulting has been named as one of the top 10 Outsourcing Consulting Companies by technology thought leader Pharma Tech Outlook magazine. Pharma Tech Outlook brings trends and breakthrough service providers and technologies to its readers, which include the most senior corporate technology decision-makers in the pharmaceutical and life science industries. “We are thrilled to …

Navigating the US payer landscape and the evolving influence of ICER

Securing optimal reimbursement and patient access in the US is complex – and it’s likely to become even more complex over the months and years to come. Here’s the good news: market access success doesn’t have to stretch your budgets or create more work. A great place to reinvigorate your thinking is this collection of …

Fishawack Health expands its global market access and HEOR capabilities with the acquisition of PRMA Consulting

Fishawack Health bolsters its strong strategic offering by acquiring PRMA Consulting – a global market access and HEOR firm with deep US, European, and Asia-Pacific expertise We are delighted to welcome market access and health economics and outcomes research (HEOR) consultancy PRMA Consulting to the Fishawack Health pack. The acquisition follows the addition of US-based …

Disease area review of psoriasis and global value dossier for an immunological asset in dermatology

Designing a GVD that meets local payer requirements

Designing an optimized Global Value Dossier (GVD) supports the efficient development of high-quality local HTA submissions that meet affiliate needs and local payer requirements. These slides are from our on-demand webinar “How to build an optimized GVD to populate local HTA/payer templates” where market access experts discuss: common omissions found in GVDs how to optimize the …

Welcoming our Senior Director and Head of Market Access & HEOR in Asia-Pacific

In this update, Andrea explains how he will be driving patient access in the region.

The digitalization of healthcare: are you ready?

Written by Fishawack Health Digitalization is rapidly transforming healthcare, from the increasing trend of hospitals without walls to the power of technology to optimize value-based care.  In this edition of Delta magazine, industry experts uncover the opportunities in the evolving digital landscape and reveal how healthcare companies can compete. Download Delta magazine from the Fishawack Health website to explore:  The rise of the healthcare social media influencer  The growing trend of hospitals without walls  How AI is revolutionizing clinical trial recruitment  The art of digital …

Information is pharma’s new competitive advantage – make sure you protect it

In this update, Kurt Haynes, security consultant, explains why information security matters in market access and shares four simple steps to help you improve security.

D&I update: the first of our international diversity and inclusion training sessions

When colleagues joined the first of our international D&I update sessions, they discussed how diversity and inclusion impacts their working relationships and learnt more about encouraging others to bring their whole selves to work. “Our diversity and inclusion training is being incredibly well received.” says Jayne Sykes, Chief Operating Officer.  “We have a large, diverse team around the world and these updates are helping colleagues to understand more about why our culture of inclusion …

Market access for regenerative medicines and rare disease therapies

This free collection of case studies offers insights and recommendations for market access for regenerative medicines and rare disease therapies. Market access strategies for regenerative medicines, and rare and orphan disease treatments are particularly complex. This collection of case studies illustrates some of the challenges and opportunities for manufacturers, including: mapping the policy landscape and …

Gaining the most benefit from your market access digital applications

We’d like to welcome Rozz Chowdhury, Client Excellence Manager, to our team.

Showcasing the women who are pioneering market access technology

In this update, we showcase our four IT product visionaries. These are women who are challenging the status quo of pharmaceutical market access through innovations in technology. Why are there so few women in IT?  Data from the Women Tech Network1 shows that in Europe only 17% of information and communications technology (ICT) specialists are women, and only 34% of Science, Technology, Engineering, and …

Writing a GVD that avoids common omissions

How a well-written GVD can save time and resources for pharmaceutical market access teams and help accelerate patient access. Our research shows that up to 30% of global HTA template requirements may not be met by a traditional GVD. This free download identifies 5 common omissions that, if met by global data, could improve GVD …

Diversity and inclusion in the workplace

Amazing things are possible when diversity and inclusion are woven into workplace culture, says Christina Lawrence, Head of People at PRMA Consulting.

Gender pronouns: why using gender-inclusive language at work matters at PRMA Consulting

In this update, Rozz Chowdhury (she/her), Client Excellence Manager, explains why she is sharing her gender pronouns with her colleagues and clients.

The untold stories of healthcare innovation: a new podcast

Written by Fishawack Health In this new podcast, the scientists, drug developers, and healthcare technology entrepreneurs behind the industry’s leading innovations share how they turned their ideas into products and services that truly transform lives. James Atherton and Ross Toohey from Fishawack Health chat to CEOs, life science pioneers, and healthcare tech entrepreneurs to discover how …

The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

Written by Fishawack Health Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? In this article, Fishawack Health reveals how life science companies can cut through the noise to drive uptake of innovative therapies, including novel TYK2 inhibitors. Download the full article …

Strategic overview of hepatitis B vaccine policy environment for inclusion in a GVD

The future of market access: a new model for the ‘next normal’

The new model of access strategy should build around four key pillars, says Jeff Weisel, Managing Director, APAC. In this update, Jeff explores why the shifting currents of global healthcare are dictating a new approach to market access. Just over three years ago, I published an article on “Rethinking Access” in which I set out …

Vaccine reimbursement: helping you prepare for success

This collection of case studies and considerations for conducting health economic evaluation of vaccines brings together guidancea from the National Immunization Technical Advisory Groups (NITAG) and insights from our market access work with leading vaccine manufacturers. Find out: How analysis of local NITAG/HTA requirements can help to tailor your GVD to meet local market needs …

10 considerations for conducting health economic evaluations of vaccines

There are numerous methods for conducting health economic evaluation of vaccines, and it is helpful to understand the elements of each. As a starting point, here are 10 considerations based on guidance1 from the National Immunization Technical Advisory Group (NITAG) and insights from our market access work with leading vaccine manufacturers. Systematic literature reviews are conducted by NITAGs to identify modeling inputs and published models – this is an opportunity for …

Writing a great GVD that balances a clear global value story with local payer requirements

A well-written global value dossier (GVD) can save time and resources for pharmaceutical market access teams and help accelerate patient access to new drugs and medical devices. One of the key success factors for creating a great GVD, as our Associate Director Claire Chadwick explains, is to consider the balance between the global value story …

Why a market access internship is a fantastic way to kick-start your career

In this update, Kristel Guce shares her experience of the application process, gives an insight into the market access projects she worked on, and talks about the support and encouragement she felt during her internship.

PM Society Digital Awards finalist announced: the PRMA Navigator®

In this market access update, Claire Chadwick and Bharath Rao share how it feels to be chosen as a finalist in the PM Society Digital Awards, and reveal what they think wowed the judges with their entry for the PRMA Navigator®.

Preparing for market access success in a crowded landscape: learnings from a plaque psoriasis case study

‘For successful market access in a crowded treatment landscape, early planning is the key,’ says Roslyn Weaver, Associate Director. Sharing learnings from a plaque psoriasis case study, Roslyn explores key challenges for manufacturers and presents a four-tiered approach to gathering strategic information that supports planning and decision-making. The heightened challenges for market access in a crowded treatment landscape In the years leading up to launching …

5 lessons in healthcare innovation from pioneers in care and treatment

Written by Fishawack Health In its recent podcast series, Fishawack Health interviewed the healthcare pioneers shaping the future of treatment and care. This article shares 5 key lessons for driving healthcare innovation. Read the article to find out what the experts said about: Changing patient expectations Persisting inequalities in healthcare systems The impact of healthcare technology …

LGBTQ+ History Month in the workplace

The importance of making time in the workplace to listen, recognize, and celebrate during LGBTQ+ History Month.

Menopause and work: initiatives to support employees

There are very few businesses where the experience of menopause is not touching employees, yet some working women continue to experience the symptoms of menopause in silence. In this business update, Alison Lawrence, Director at PRMA Consulting, explains five initiatives that are supporting colleagues who experience menopause symptoms at work. She also makes the case …

How an assessment of NITAG and HTA evidence requirements can help manufacturers establish the value of their vaccine

In the seventh of our series of updates examining market access for vaccines, Claire Chadwick, Director, takes us through a case study of how an assessment of national immunization technical advisory group (NITAG) and health technology assessment (HTA) evidence requirements can help manufacturers establish the value of their vaccine with decision-makers. .. A global value …

Fishawack Health welcomes new CEO Jonathan Koch

Written by Fishawack Health Jonathan (Jon) Koch has joined Fishawack Health as CEO, tasked with driving a sustainable future for the company. Jon will lead us through our next phase of growth, which is centered on building and retaining talented teams and delivering a full set of integrated services for our clients across the life science …

The team that eats together, advances together

After months of virtual communications during the Covid-19 pandemic, we were thrilled that so many colleagues could join us at our company dinner.  The evening was a wonderful opportunity to enjoy each other’s company in a safe social environment, appreciate the contribution that everyone has made to our clients’ projects, and welcome new members to the team.    “Thank you for arranging an excellent team social. It was fun to get together again face-to-face. I also …

How to build an optimized GVD to populate local HTA/payer templates

This free, 10 minute webinar discusses common omissions to avoid and provides recommendations for optimizing GVD development to populate local HTA/payer templates, leveraging the experience and digital solutions of PRMA Consulting.

US healthcare review: pandemic, politics, pricing, and the payer landscape

The COVID-19 pandemic has exposed the fault lines in how we govern and pay for healthcare, and has reinforced the need for US healthcare reforms that facilitate affordable care.  In this market access update, we explore the shifting dynamics of US healthcare in the post-pandemic era and highlights the three most potentially impactful reforms for …

5 insights for improving pharmaceutical market access in Asia-Pacific

“The reason that pharmaceutical market access professionals are excited about AsiaPacific (APAC),” says Jeff Weisel, Managing Director APAC, “is not just because of the developed markets with mature payer systems; it’s also the potential from emerging markets with larger populations and evolving payer systems.”  In this market access update, Jeff explains that while APAC markets may appear to be particularly complex, market access strategies will be improved by:  thinking of the region as two distinct groups or archetypes …

ICER and Value Assessment Frameworks: 5 key insights for biopharma

Examining the growth of Value Assessment Frameworks and why preparing for engagement in the ICER assessment process is the best way forward for biopharma manufacturers

Liz Landon joins Fishawack Health to deliver a first-class experience for colleagues

Written by Fishawack Health PRMA Consulting, a member of Fishawack Health, is pleased to welcome Elizabeth (Liz) Landon to the group in the role of Chief People Officer.  Leading our international team of HR, Talent, and Learning and Development professionals, Liz will strengthen our strategies to recruit and retain the best value, access, and evidence experts in the industry.  Liz’s mission is to deliver a first-class employee experience and she is looking forward …

Supporting the Fleet Phoenix charity in the Manchester Half Marathon

We would like to wish Jayne Sykes, Chief Operating Officer at PRMA Consulting, the best of luck this weekend as she runs the Manchester Half Marathon in support of the Fleet Phoenix charity for young people.   Fleet Phoenix is a local charity that improves the lives and wellbeing of young people and has an incredibly positive impact on the wider community. Its supportive environment, activity clubs, mentoring projects, and tailored support help young people through their personal challenges to learn and achieve their …

Economic evaluation of vaccines: why is a QALY a recommended measure of benefit?

In the sixth of our series of updates examining market access for vaccines, Vanya Nikolova, Senior Consultant, shares why a quality-adjusted life-year is a recommended measure of benefit in the economic evaluation of vaccines, and considers discounting of costs and health benefits in vaccine economic models across markets. .. On this slide you can see …

Using economic models and cost-utility analyses to explore the cost-effectiveness of vaccines

In the fifth of our series of updates examining market access for vaccines, Vanya Nikolova, Senior Consultant, guides us through the use of economic models and cost-utility analyses to explore the cost-effectiveness of vaccines. .. Using economic models to explore the cost-effectiveness of different vaccine candidates The type of economic model that is used in …

Addressing inequities in access to healthcare: 4 recommendations for biopharma manufacturers

When planning for access to healthcare it is important to recognize the difference between health inequality and inequity says Alisha Robert, Consultant at PRMA Consulting, a member of Fishawack Health.

Black History Month: celebrating 10 pioneers in healthcare

In the first of two articles, our Diversity, Equity, and Inclusion team shares why PRMA Consulting recognizes and celebrates Black History Month, showcases ten Black pioneers in healthcare, and offers three ways of recognizing Black History Month in the workplace.   Why we recognize Black History Month in our international workplaces  Black History Month is a compelling and necessary moment to draw attention to, reflect on, and celebrate the achievements of, some of the people have advanced healthcare …

10 inspiring Black healthcare pioneers

In the second of our articles recognizing and celebrating Black healthcare pioneers, our Diversity, Equity, and Inclusion team showcases inspiring individuals who have led positive and life-changing advances in life-sciences.

How my market access internship opportunity helped me develop my individual skillset

It was a pleasure to welcome Jacob Sanderson to the team and we hope this update gives an insight for others who are thinking about the benefits of working as a market access intern.

Empowering people of color in clinical trials: a reflection on Martin Luther King Jr. Day

On this special day, we reflect on one element of racial representation in healthcare, that of inequality in clinical trials, and highlight an example of one woman, Karen Peterson, who is driving positive change for people of color.

Sheena Amin-Liebman joins Fishawack Health in the newly created role of Diversity & Inclusion Director

Written by Fishawack Health PRMA Consulting, a member of Fishawack Health, is pleased to welcome Sheena Amin-Liebman to the group in the newly created role of Diversity & Inclusion Director. “Fishawack Health has developed a bold D&I strategy focused on creating meaningful change and moving the needle in the agency and consultancy worlds for employees and …

New experts strengthen client partnerships in PRMA Consulting’s Asia-Pacific market access team

PRMA Consulting welcomes two new consultants to its Asia-Pacific (APAC) team.

Market access for biotechnology

An on-demand webinar for biotechnology manufacturers to discover the latest recommendations for market access success.

Evaluation of vaccines: guidance on evidence and modeling requirements

In the fourth of our series of updates examining market access for vaccines, Vanya Nikolova, Senior Consultant, summarizes the evaluation guidance from national immunization technical advisory groups (NITAG) and health technology assessment (HTA) agencies in France, Germany, Italy, Spain, the UK, and the US. .. NITAGs or HTA agencies publish guidance on evidence and modeling requirements …

How pricing models for vaccines vary between countries

In the third of our series of updates examining market access for vaccines, Vanya Nikolova, Senior Consultant, guides us through the variation in pricing models for vaccines across five countries: Italy, Spain, Germany, the UK, and US. .. Similarly to pharmaceuticals, pricing models for vaccine products vary across markets. Italy and Spain: pricing models for …

Vaccine appraisals in France: who are the key stakeholders?

In the second of our series of updates examining market access for vaccines, Vanya Nikolova, Senior Consultant, guides us through six of the key stakeholders that are involved in the approval of new vaccines in France, including the: French National Authority of Health (HAS) Technical Committee on Vaccinations (CTV) Transparency Committee (TC) Committee for Economic …

Demonstrating the value of vaccines: global NITAG and HTA requirements

Now more than ever, HEOR and market access teams need to ensure they have a deep understanding of vaccine evaluation requirements to plan for success. These slides are from our on-demand webinar “How to demonstrate the value of vaccines: NITAG and HTA requirements” where market access experts discuss: which stakeholders are involved in vaccine evaluation, and …

Fishawack Gives Back: supporting healthcare causes through our new philanthropic program

Written by Fishawack Health We are pleased to announce the launch of Fishawack Gives Back, a philanthropic initiative that spans our offices across the globe. The aim of the scheme is to support and showcase wider healthcare programs and well-being causes.  PRMA Consulting is a member of Fishawack Health, and our global teams are united in a common goal …

Women in technology: a career in an organization that values diversity

Research from Women in Technology1 shows that the science, technology, engineering, and mathematics industries face the challenge of encouraging future generations to choose a career in those fields.  In this update, Rozz Chowdhury, Client Excellence Manager shares her experience of growing up without role models of women in technology and the sense of value she felt when she joined the IT team …

Federal drug price regulations: is ‘Build Back Better’ a direction-altering precedent leveraging copycat actions?

“Improving drug affordability for patients will come at a cost,” says Nicole Lodowski, Senior Director and PRMA US Practice Lead, as she considers the federal drug price regulations within new Build Back Better1 legislation and the potential effect on pharmaceutical manufacturers and patients. Federal drug price negotiations Sections of Build Back Better will permit the …

Recognizing Disability History Month in the workplace: 4 ways you can raise awareness at work

Disability History Month provides a platform to raise awareness within the workplace and celebrate the pioneers who are challenging and changing perceptions.

Welcoming FIDE, a leading network of dermatology experts, to the Fishawack Health group

Written by Fishawack Health PRMA Consulting, a member of Fishawack Health, is pleased to welcome FIDE, a leading network of dermatology experts, to the group.   “I’m incredibly excited to welcome such a talented team to our organization,” says Jonathan Koch, Fishawack Health CEO.   “FIDE’s key opinion leaders will add a unique lens to our services for our dermatology clients – one that …

The role of NITAGs and HTA agencies in decision-making for vaccines

In the first of our series of updates examining market access for vaccines, Marie Chivers, Associate Director, guides us through some of the stakeholders involved in the approval of new vaccines, looks at the role of NITAGs as critical stakeholders in decision-making for vaccines, and considers the varying role of HTA agencies in the vaccine …

Demonstrate the value of vaccines: 7 updates examining NITAG and HTA requirements

Health economics and outcomes research (HEOR) and market access teams responsible for vaccines need a deep understanding of evaluation requirements from national immunization technical advisory groups (NITAGs) and health technology assessment (HTA) agencies. Read these seven updates to gain: an understanding of the global requirements of NITAGs and HTA agencies for vaccine evaluation insights into …

Michelle Wing joins PRMA Consulting as Associate Director, leveraging her unique market access expertise to accelerate access to therapies

Market access is fundamental to accelerating access to therapies that have the potential to improve the lives of patients and those close to them.

Team Member Achievement Awards 2021

This year’s Fishawack Health Team Member Achievement Awards were an opportunity to celebrate our colleagues and recognize the values of authenticity, valuing difference, owning the challenge, playing for the team, and enjoying the journey.  We’d like to thank all the colleagues who made nominations and congratulate the individuals who won the US$1,000 Awards. As a member of Fishawack Health, the team at PRMA Consulting were thrilled to learn …

How Paul Abi-Aad is strengthening value, evidence, and access collaboration in his new role as Client Partnership Lead

I’m Paul Abi-Aad and I’m excited to be working with clients in a new role as Client Partnership Lead, focusing on strengthening value, evidence, and access collaborations with leading, international biopharma manufacturers. If you would like to know more about how I and the Client Partnership team at PRMA Consulting can help you optimize your …

Something for everybody? A holistic approach to market access in emerging markets

In this Asia-Pacific (APAC) market access update, Jeff Weisel (Managing Director, APAC) of PRMA Consulting moves the focus to emerging markets.

Gong hei fatt choy and gong xi fa cai: wishing you great happiness and prosperity this Chinese New Year

Happy Chinese New Year to all our colleagues and clients. 2022 is the Year of the Tiger, a symbol of strength and bravery, which is especially meaningful at a time of welcoming the new and the good.  Our colleague Ella Toh, Analyst, shares her thoughts of Chinese New Year 2022 with us.  “Before I moved …

Employee wellbeing scores 93% at PRMA Consulting and bucks workplace trends

“Fostering employee wellbeing is good for people and the organization”1 yet, in some organizations, 53% of employees say bosses don’t care about their wellbeing.2 We are proud that colleagues at PRMA Consulting think differently and, in a recent employee survey, 93% of respondents said that their manager genuinely cares about their wellbeing and makes them …

Recognizing the International Day for the Elimination of Racial Discrimination in our workplaces

March 21 is the International Day for the Elimination of Racial Discrimination. In this update, colleagues from across our international workplaces give an insight into the day, and why and how we recognize it. What is the International Day for the Elimination of Racial Discrimination?  The United Nations organizes this annual international event as a …

Transgender Day of Visibility: the importance of workplace inclusivity and allyship

March 31 is the international Transgender Day of Visibility (TDoV); an annual, worldwide event that celebrates the lives and contributions of people who are transgender. The day importantly raises awareness of the discrimination faced by so many people all around the world and the work that needs to be done to improve equity, equality, and …

The insights that are strengthening connections amongst new members of the PRMA Consulting team

Did you know that all new members of the PRMA Consulting team are invited to an Insights® Discovery workshop? This update uncovers why the profile and workshop are staple features in their induction program. Colleagues also share how putting their insights into practice is enabling them to support our diverse and inclusive culture, improve well-being, …

Fishawack Health expands its value, evidence, and market access capabilities with the acquisition of HEOR consultancy Policy Analysis Inc. (PAI)

Image: The Policy Analysis Inc. leadership team (from left to right), Gerry Oster, PhD, Managing Partner; Derek Weycker, PhD, Partner; Thomas Delea, MSIA, Partner; Chad Rose, Chief Operating Officer. With the addition of PAI, our Policy, Access, Value, and Evidence (PAVE) team offer an impressive suite of end-to-end services and unsurpassed geographic reach. PRMA Consulting …

Are your market access digital applications delivering maximum value? 5 KPIs every digital product leader needs to know

Do you know how well your market access digital solutions are performing? Are they meeting your global and affiliate team’s needs? Are they meeting your organization’s value, evidence, and access needs? If you aren’t sure, Onisim Gabrian, Product Manager, shares his checklist of five key metrics you can use to evaluate if your applications are …

International Women’s Day: Deborah Keller, Chairperson of Fishawack Health, on gender, resilience, and yoga

International Women’s Day is celebrated each March, and to recognize the day, Deborah Keller, Chairperson of Fishawack Health (FH), joined us for a humorous and relatable conversation to share her career highlights, from chemist to Chairperson. The fireside chat was hosted by David Sykes, Head of Value, Evidence, and Access, and Executive Sponsor of the …

Neurodiversity in the workplace: the importance of neurodivergent business leaders as role models

“All of us think about and experience the world differently,” says Clare Jones, Senior Director, “but what makes working at PRMA Consulting so wonderful is that we embrace, celebrate, and leverage our differences to great personal and business effect.

Καλό Πάσχα, Kalo Pascha, Happy Orthodox Easter!

Καλό Πάσχα, Kalo Pascha, and Happy Orthodox Easter to all our colleagues and clients! We wish you a peaceful and happy time with your families and friends.  Orthodox Easter is an important event, not only because of what it signifies but because of the customs and traditions that we share; and now that the Covid-19 …

Ramadan Kareem

Ramadan Kareem to all our international colleagues and clients! We wish you a peaceful and happy time with your families and friends. In this update, Muhammed Karolia, Principal Editor, shares his own experiences of Ramadan and explains how he is inviting colleagues across the world to join him during his fast.  “Ramadan is the ninth …

Vaisakhi: my celebration of joy and connection

“For me, Vaisakhi means togetherness,” says Ally Robert, Consultant, “and it’s those connections that I celebrate at this time of year. I wish all my colleagues and clients a joyous Vaisakhi and a wonderful New Year.”  Vaisakhi: a colorful celebration on April 13 or 14 each year  “One of the days I looked forward to …

Try this omnichannel maturity tool to gain an instant analysis of your omnichannel readiness

The Fishawack Health omnichannel maturity tool is designed for biopharmaceutical, healthcare technology, and wellness companies that are driven to develop integrated and customer-centric omnichannel experiences. This simple 8-question tool is divided into 4 sections to help you understand your organization’s level of omnichannel maturity. Once you have completed the questionnaire, you will receive tangible recommendations …

Omnichannel recommendations for the life science industry

In this free issue of Delta magazine, the Medical, Marketing, and Consulting experts of Fishawack Health share their recommendations for creating meaningful omnichannel stakeholder experiences and reveal a proprietary tool for measuring omnichannel maturity. What are omnichannel experiences? Omnichannel experiences are dynamic and meet the stakeholder’s needs seamlessly at a variety of touch points. While …

Skysis and PRMA Consulting look forward to connecting with you at Asembia 2022

Asembia Speciality Pharmacy Summit 2022, May 2-5, Las Vegas is a great opportunity to connect face-to-face and explore innovative approaches to pressing US market access challenges. “Patient access to treatments is becoming more complex in the US. The biggest challenge that we will be exploring at Asembia 2022 is the vast number of ‘unknowns’ as …

How to demonstrate the value of vaccines in line with global NITAG and HTA requirements

Since 2020, vaccine development and evidence-based evaluation by national immunization technical advisory groups (NITAGs) and health technology assessment (HTA) agencies have become important line items in pharmaceutical investment and strategic planning.  Now more than ever, HEOR and market access teams need to ensure they have a deep understanding of vaccine evaluation requirements to plan for …

Policy, Access, Value, and Evidence: 4 key trends for 2022

The Policy, Access, Value, and Evidence landscape is becoming increasingly complex and challenging, but several key trends can be discerned. In this update, we highlight the disconnects that are emerging between the evidence regulators and payers expect the growing need to provide longer-term trial data and real-world evidence, and the trend towards more complex managed entry or …

Eid Mubarak

Eid Mubarak to all our international colleagues and clients! We wish you a peaceful and happy time with your families and friends. In this update, Muhammed Karolia, Principal Editor, explains the Eid festival and how he celebrates with his family.  “Similar to the celebrations of Christmas and Easter, Muslims also celebrate two major festivals in …

Adjusting to the increasing focus on value-based pricing

Value-based pricing and contracting is still an area of great uncertainty in the US. Some payers embrace the opportunity for these agreements, striving to be innovative and forward–thinking, while many others cannot justify the logistical complications associated with the data and outcomes required to make these succeed.   Currently, many payers see these as “PR stints”, …

Critical factors to successful US payer negotiations

As drug prices soar, therapy areas become saturated with costly innovations that have to compete with cheaper generics, and the prevalence of chronic conditions increases with an aging population, price negotiations are commanding more attention.   Engaging with US payers early, transparently, and consistently can help to establish positive relationships throughout the product lifecycle, which will …

ISPOR Conference 2022: from pipeline assets to patient access

We’ll be at the ISPOR conference in Washington, DC, and online during the virtual conference May 15–18, 2022. Come and meet Policy Analysis Inc. (PAI) and PRMA Consulting at booths 306 and 405 for the latest news about our end‑to‑end Value, Evidence, and Access services. Showcasing end-to-end Value, Evidence, and Access services at ISPOR Conference …

Key Trends in Asia-Pacific

As companies seek to maintain value in established markets, and focus grows on emerging markets, the strategic importance of Policy, Access, Value, and Evidence is increasing – and the need for an integrated 360 approach is becoming ever clearer. In this update Jeff Weisel, Managing Director, APAC explores current trends and challenges in APAC markets …

Supporting mental health awareness in our international workplaces

“PRMA Consulting takes mental health seriously,” says Tomoko Bowden, People Coordinator. “As a team, we are committed to supporting our colleagues and helping normalize conversations around mental health.” In this update, Tomoko shares why mental health awareness and support is important within our international teams, and four ways we support colleagues with their mental health.  “A …

Pride month 2022: why we recognize pride in our workplaces

Why earlier value assessment of your assets through a payer lens makes a difference.

Understand what payer relevant challenges and opportunities may present themselves for early pipeline assets and discover ways of making those insights drive more positive market access outcomes.  These slides are from our on-demand webinar “Increase your influence in early pipeline planning: why earlier value assessment of your assets through a payer lens makes a difference.” …

Fishawack Health is proud to announce that Avalere joins its team

Fishawack Health (FH) is proud to announce that leading US-based healthcare policy, market access, and transformation firm, Avalere Health (Avalere), is joining its team. We spoke to Elizabeth Carpenter, President of Avalere, and David Sykes, President of Policy, Access, Value, and Evidence (PAVE) at FH, and Founding Partner at PRMA Consulting, about the partnership and …

Fishawack Health adds leading US healthcare policy experts Avalere

We’re bolstering our commercialization service offering with our largest addition to date, welcoming US-based policy, market access, and transformation leader Avalere to our group. We’re delighted to welcome leading healthcare consulting and advisory firm Avalere Health (Avalere) to our group. The move marks the largest expansion of Fishawack Health (FH) to date and allows clients …

Why client delivery excellence is built on a foundation of team development

“Our colleagues are the heart of our business,” says Vicky O’Connor, Executive Director, “and we want to give them every opportunity to thrive.” In this update, Vicky explains why an organization-wide focus on wellbeing and career experience helps her colleagues own the challenge of delivering innovative policy, access, value, and evidence services to biopharma clients.  “Over …

Increase your influence in early pipeline planning: why earlier value assessment of your assets through a payer lens makes a difference.

As aspiring treatments begin their journey through clinical development programs, a range of decisions need to be made, many of which can ultimately impact market access potential.  Evolving treatment landscapes and advances in scientific and medical innovation increase the pressure on payers and manufacturers need to be making well planned and informed decisions about pipeline assets …

Accelerating the submission process for 16 markets through simultaneous development of HTA dossiers

Digital health technologies: 5 challenges for market access and reimbursement

“Digital health technologies will increasingly disrupt the development and access landscape,” says Paul Abi-Aad, Client Partnership Lead. In this market access update, Paul explores why current market access frameworks do not adequately address the unique risk/benefit profile of many digital health technologies, and summarizes 5 access challenges that biopharmaceutical manufacturers may experience. Digital health technologies …

CMS announces the Enhancing Oncology Model as the successor to the Oncology Care Model

As US government and commercial payers continue to search for solutions to spiraling costs in oncology care, new approaches to rein in costs and improve quality of patient care are needed. To address these challenges, the Centers for Medicare and Medicaid (CMS) has announced an evolution of the 2015 Oncology Care Model (OCM) with the …

Surviving versus thriving as a woman working in tech

“I work in tech because I love thinking outside of the box and working with innovative, like-minded people,” says Lizzie Quarman, Client Excellence Coordinator, Digital Team. “But at the same time, there are challenges that, as a woman working in tech, I have had to overcome.” In this update, Lizzie explores some of the challenges she …

Early scientific advice support for an orphan drug for a rare cardiovascular disease

Understanding the concept of early scientific advice and its purpose across HTA markets

Uncertainty and inappropriate trial design are the main reasons why medicines fare badly in health technology assessments (HTA). HTA scientific advice recommendations can identify key payer evidence requirements and areas of uncertainty, and when implemented result in stronger HTA submissions.  These slides are from our on-demand webinar “Understanding the concept of early scientific advice and …

Right sizing your approach to market access to influence how value is captured and demonstrated in early clinical development

In the second in a series on increasing market access influence during early pipeline planning, Andrea Hamlin, Associate Director, highlights some of the stakeholders who can influence market access, summarizes 4 key trends in the policy, access, value, and evidence landscape, and highlights the need to right size your approach to market access to influence …

Why earlier value assessment of your assets through a payer lens makes a difference for market access

In the first of a series on increasing market access influence during early pipeline planning, Andrea Hamlin, Associate Director, explains why earlier value assessment of your assets through a payer lens makes a difference. This starts with an overview of how external factors are driving the increasing need to assess the value potential for your …

Playing for the team and enjoying the journey are two company values that resonate with me

Claire Chadwick, Director at PRMA Consulting, explains why she finds a career in market access rewarding and what the company values of “We play for the team” and “We enjoy the journey” mean to her.  Helping accelerate market access to innovative treatments is so rewarding   The most rewarding part of working in market access for …

“Stronger Together, Majulah!” – A celebration of the National Day of Singapore

“For us, the National Day of Singapore is a time to reflect on the past and celebrate the present and our future,” say Ariel Tan and Vesshnu Sutharsan, Analysts. In this update, they share their experience of the day and, together with the team from our office in Singapore, wish all colleagues and clients a …

5 ways to smartly manage your market access information using digital applications

In this update, Bharath Rao, Product Owner, explores 5 common anxieties experienced by market access professionals when managing information, and shares news of some exciting developments in technologies that enable smooth collaboration and smarter working.  Strategy may be queen or king in policy, access, value, and evidence, but the underpinning insights-led information does not develop …

Enjoying the journey as a market access intern at PRMA Consulting

It was a pleasure to welcome Michaela Lysakova-Ivanova to the team during her market access internship. We hope this update from Michaela gives an insight for others who are thinking about the benefits of working as a market access intern.  This market access internship was the right choice  I was studying International Health Policy at …

Principles and benefits of HTA early scientific advice

Uncertainty and inappropriate trial design are key reasons why medicines may fail to achieve optimal outcomes in health technology assessment (HTA). Scientific advice from HTA agencies can identify areas of uncertainty regarding payer evidence requirements, and when implemented can result in stronger HTA submissions.  In this update, we summarize the key principles and benefits of …

New malnutrition reporting measure, developed by Avalere Health and the Academy of Nutrition and Dietetics, is now available for reporting 

The innovative Global Malnutrition Composite Score, approved by Centers for Medicare & Medicaid Services (CMS), will empower providers to deliver higher quality care to patients. Hospitals facilities will be able to improve the quality of care for patients with malnutrition and reduce hospital stays and costs by leveraging a new measure developed by our policy …

Early preparedness before your US market access and HEOR teams are established: 5  key considerations 

In the US, obtaining FDA approval is only one step within the often complex journey of achieving market access success. Beyond this approval, successfully navigating and addressing the various and constantly evolving priorities and evidence needs of US payers becomes the main stumbling block, which are often not considered until it’s too late. In this …

What US market access professionals need to know about pre-approval information exchange

As payers’ evidence needs continue to evolve and formulary and budgetary decision-making becomes more complex, manufacturers have a prime opportunity to create added value by engaging with payer customers earlier and more often through pre-approval information exchange (PIE) programs.  This free article discusses:  why, historically, manufacturers have been limited in what information they were permitted …

US pre-approval information exchange: building a pre-approval information exchange strategy in 3 steps

As payers’ evidence needs continue to evolve and formulary and US budgetary decision-making becomes more complex, biopharma manufacturers have a prime opportunity to create added value by engaging with payer customers earlier and more often through pre-approval information exchange (PIE) programs.  What is pre-approval Information exchange?  PIE is the exchange of clinical and healthcare economic …

Real-world example: a PIE program with US payers to support preliminary access for a new immunology product 

World Alzheimer’s Month: know dementia, know Alzheimer’s

“Know dementia, know Alzheimer’s” is the theme for World Alzheimer’s Month 2022.1 In this update, Heather Hewett, Medical Writer and member of our Diversity, Equity, and Inclusion team, shares some initiatives that you can get involved in. September is World Alzheimer’s month Dementia is a general term used to describe a decline in cognitive ability …

A unique opportunity to learn, collaborate, and create solutions: my experience as a market access intern at PRMA Consulting

It was a pleasure to welcome Franziska to the PRMA Consulting team during her market access internship. In this update, she shares her thoughts on working with us and suggests how other students can make the most of their time working as a market access intern. An internship in market access is an amazing way …

The patient voice – the value of patient-reported outcomes in HTA 

The patient’s voice is increasingly important in securing access for therapies in markets and demonstrating how they deliver and radiate value across healthcare systems. Conveying the nuances of patient experience as a result of their condition and the effects of therapy – and developing methodologies for assessing and rating these by appraisal authorities – is …

The importance of LGBTQ+ role models at work

In this update, colleagues from our LGBTQ+ employee network group share why they believe in being visible role models at work, and we offer three ideas for anyone wanting to explore what it means to be an LGBTQ+ role model in the workplace.  The need for LGBTQ+ role models in the workplace   In a recent …

Real-world evidence: the importance of effective collaboration with healthcare professionals 

“Engagement with healthcare professionals is crucial for generating real-world evidence,” says Mariam Bibi, Senior Director, Global RWE, in her published article “Maximizing the value of your asset by leveraging real-world evidence”. In this excerpt, Mariam explains how to strengthen your collaborative approach to generating real-word evidence (RWE) with healthcare professionals and other stakeholders. Why engaging …

PRMA Consulting as Knowledge Partner in Zuellig Pharma’s 2nd Healthcare Access Summit – “Building a Healthier Asia: Empowering more equitable access to healthcare innovation” 

5 October 2022  9.30am – 3pm SGT (GMT +8)  Zuellig Pharma is on a mission to make healthcare more accessible to all. As one of the largest healthcare service groups in Asia, it provides world-class distribution, digital, and commercial services to support the growing healthcare needs in the region.  Working in partnership with PRMA Consulting, …

How real-world evidence supports market access for high cost/low volume therapies 

Real-world evidence (RWE) can be leveraged by biopharmaceutical manufacturers to highlight the value of high-cost and low-volume therapies and highly targeted novel therapeutic approaches. In this excerpt from her published article, Mariam Bibi, Senior Director, Global RWE, explains why manufacturers are developing their real-world evidence strategies earlier in the clinical development process, and makes recommendations …

Several changes to adult vaccine access enacted through the IRA 

The Inflation Reduction Act will expand adult vaccine access by mandating coverage without cost–sharing for all adult vaccines in Medicare Part D and Medicaid – an update from Avalere, a member of Fishawack Health. On 16 August 2022, President Biden signed the Inflation Reduction Act (IRA) into law. The legislation includes a variety of healthcare …

National Healthcare Security Administration (NHSA) of China announces drug list up for National Reimbursement negotiation

On 7 September, NHSA announced 2022’s National Reimbursement Drug List (NRDL) applications that have passed the preliminary review and are up for expert assessment, negotiation, and bidding. Background The NRDL listing has 4 steps: manufacturer application submission, preliminary review of application, expert assessment, negotiation and bidding. Preliminary review is an evaluation process to determine whether …

What is Real-world evidence?

Real-world evidence (RWE) is observational evidence that is generated in routine clinical practice.  RWE is generated by analyzing real-world data (RWD), which can come from a variety of sources (collected retrospectively or prospectively). It can be generated from several types of trial and study design, including observational studies, surveys, and pragmatic trials, and from a …

Medicare negotiation could reduce manufacturer revenues by US$165 billion 

Analysis of updated Senate drug pricing legislation shows Medicare negotiation could reduce manufacturer revenues by US$165 billion in Part D and US$290 billion in Part B from 2026 to 2032 – an update from Avalere, a member of Fishawack Health. On 6 July 2022, the Senate Finance Committee released its updated draft of the drug pricing provisions …

Maximizing the value of your asset by leveraging real-world evidence 

In modern clinical research, data are key to the successful development and access of new drugs, and can help expedite the availability of effective treatments. Manufacturers that develop novel targeted therapies, especially in the rare disease space, can face challenges with funding and approval where data are perceived to be lacking.  This free article explains …

How a new technology add-on payment (NTAP) works

Additional Medicare payment options are available for new, high-cost technologies used in the inpatient setting–an update from Avalere Health, a member of Fishawack Health. For an up-to-date look into new technology add-on payments (NTAPs) and the most recent proposed changes to this payment designation from the Centers for Medicare & Medicaid Services (CMS), please see …

Black History Month 2022: Our Diversity, Equity, and Inclusion team share what Black History Month means to them

Black History Month is both a time to celebrate, to learn, and understand black history and culture. Our Diversity, Equity, and Inclusion team share what Black History Month means to them and why it should be recognized. Peter Okorozo, PRMA Consulting “Early in life when we learned about black history, it focused a lot on …

Understanding the concept of early scientific advice and its purpose across HTA markets

Uncertainty and inappropriate trial design are the main reasons why medicines fare badly in health technology assessments (HTA). HTA scientific advice recommendations can identify key payer evidence requirements and areas of uncertainty, and when implemented result in stronger HTA submissions.  This webinar explores the benefits, processes, and key considerations from an industry perspective of HTA …